Skip to content
2000
Volume 19, Issue 18
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The proteasome inhibition has been proved to be effective in the treatment of multiple myeloma and other malignancies. In addition to direct antitumor effects, proteasome inhibition also exerts strong effects on immune cells, such as T cells, B cells and DCs. Therefore, proteasome inhibition, through the utilization of small molecule drugs like bortezomib, could be used therapeutically to modulate immune responses in transplantation. In the current review, we discuss the emerging data, both preclinical and clinical, of using proteasome inhibition in treating complications of transplantation, such as antibody-mediated organ rejection (AMR) and graft-versus-host disease (GVHD). The therapy based on proteasome inhibition may present substantial opportunities as new therapeutic paradigms in transplantation.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/13816128113199990308
2013-06-01
2025-04-22
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/13816128113199990308
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test